Best Life Sciences Companies in Hayward, United States
The 55 best Life Sciences companies in Hayward, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: RefleXion.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Hayward
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RefleXion Provider of biology-guided radiotherapy system | $490M | 32 mo ago | 257 257 → 154 (-40%) | Samuel Mazin Founder and CTO | WordPressSentryApple iCloud Mail+37 | Series F | — | — |
| 2 | CymaBay Therapeutics Developer of therapeutics for liver and other chronic diseases | $276M | 59 mo ago | 23 | — | — | Acquired | 378 patents Selective PPARδ agonist compounds for treating liver and cholestatic diseases. | — |
| 3 | Moximed Developer of an implant for pre-arthroplasty osteoarthritis patients 53Funding top 18%Moat top 19%Product top 26%Patents top 31% All 11 signals ▾Fundingtop 18% Moattop 19% Producttop 26% Patentstop 31% Innovationtop 34% Growthtop 35% Techbottom 49% Talentbottom 49% Globalbottom 44% Marketbottom 26% Newsbottom 18% Funding: Raised $262M across 7 rounds · 7 rounds over 18 yrs (0.4/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 271 patents rank vs industry peers · Fliar Intelligence Index 53/100 | $262M | 23 mo ago | 15 | Josh Makower Founder & Chairman | WordPressApple iCloud MailMicrosoft 365+20 | Series D | 268 patents Implantable and transcutaneous orthopedic devices for joint load reduction and energy absorption | — |
| 4 | Arcus Biosciences Developer of immune-focused cancer therapies targeting the ATP-adenosine pathway | $227M | 104 mo ago | 577 | — | WordPressMarkerApple iCloud Mail+29 | Public | 468 patents Small-molecule cancer therapeutics and predictive biomarkers targeting oncogenic pathways. | — |
| 5 | OptiScan Biomedical Developer of a continuous monitoring system for use in the surgical intensive care unit (SICU) | $220M | 87 mo ago | 67 | Peter Rule CEO | — | Deadpooled | 289 patents Point‑of‑care fluid analyzers for glucose and biomarker measurement using disposable cassettes | — |
| 6 | Aradigm Developer of inhalable therapies for respiratory diseases | $199M | 107 mo ago | 23 | — | — | Deadpooled | 223 patents Liposomal inhalable antibiotics targeting pulmonary non‑tuberculous mycobacterial infections | — |
| 7 | Solta Range of aesthetic products | $105M | 151 mo ago | 6,355 | — | Optimizely Content ManagementSentryGoogle Maps+25 | Acquired | — | — |
| 8 | Spotlight Therapeutics Developer of cancer therapeutics using gene editing | $81M | 33 mo ago | 32 | — | — | Deadpooled | — | — |
| 9 | Acologix Therapeutics for the treatment of metabolic disorders of kidney and bone | $70M | 245 mo ago | 13 | — | — | Series C | 49 patents Peptide therapeutics for cartilage and bone regeneration with high‑temperature stability | — |
| 10 | Rondo Therapeutics Developer of therapeutic antibodies to treat cancer | $67M | 52 mo ago | 15 | Shelley Aldred Co-Founder & CEO | — | Series A | — | — |
| 11 | Aurora Algae Provider of technology for algae based products | $62M | 165 mo ago | 6 | Gregory L. Bafalis CEO & Board Member | — | Deadpooled | 87 patents Genetically engineered algae for enhanced lipid production and biofuel conversion | — |
| 12 | Anthera Vegan nail care: French-made, ethical, fortifying, hydrating, and protective | $55M | 102 mo ago | 24 | Craig Thompson CEO | — | Public | — | — |
| 13 | Calyx Therapeutics Developer of small molecule therapeutics for Diabetes and Rheumatoid arthritis | $44M | 295 mo ago | — | Mark Schwartz CEO | — | Acquired | — | — |
| 14 | Predicine Developer of liquid biopsy assays and biomarker discovery for cancer | $41M | 71 mo ago | 23 | Shidong Jia Co-Founder & CEO | — | Series B | 37 patents Liquid biopsy platforms for cancer MRD detection, methylation profiling, and multi-analyte monitoring | — |
| 15 | Liposonix Aesthetic skin solutions provider: Thermage, Clear + Brilliant, Fraxel, and VASERlipo | $40M | 264 mo ago | 6,139 | — | — | Acqui-Hired | 118 patents Integrated therapeutic ultrasound systems with cartridge-based drug/gel delivery and real-time monitoring. | — |
| 16 | RayVio Online slot gaming: Thrilling entertainment with diverse themes and winning potential | $35M | 122 mo ago | 9 | — | — | Deadpooled | 78 patents UV-LED based liquid disinfection and monitoring systems for medical and water treatment | — |
| 17 | Quartzy Provider of web-based platform for labs management 67Funding top 24%Growth top 26%Tech top 37%Innovation top 38% All 10 signals ▾Fundingtop 24% Growthtop 26% Techtop 37% Innovationtop 38% Moattop 39% Producttop 42% Marketbottom 49% Talentbottom 49% Newsbottom 47% Globalbottom 37% Funding: Raised $33.9M across 6 rounds · 6 rounds over 14 yrs (0.4/yr) Growth: Headcount 54 → 97 (+80%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 67/100 | $34M | 3 mo ago | 97 97 → 92 (-5%) | Adam Regelman Co-Founder & CPO | Cart FunctionalityHubSpot CMS HubFacebook Login+28 | Series C | — | 1 job opening · 2 partnerships |
| 18 | Biolog Provider of cell-based phenotyping technologies and assays | $18M | 17 mo ago | 27 | — | WordPress Block EditorWordPressMySQL+25 | Series A | 37 patents Veterinary vaccines for swine viruses and methods to neutralize microbial toxins | — |
| 19 | Solexa Develops Genome sequencing technology | $14M | 235 mo ago | 11,000 | Francis deSouza CEO | — | Acquired | 64 patents High-throughput DNA sequencing by synthesis using parallel oligonucleotide extension | — |
| 20 | Kryptos Biotechnologies Biotechnology company illuminating complex diseases with innovative diagnostic and life science solutions | $13M | 27 mo ago | 7 | Jinyong Lee Co-Founder & COO | — | Series A | 47 patents Microfluidic nucleic‑acid extraction and optical PCR sample‑processing platforms | — |
| 21 | Mendel Biotechnology Online retailer of apparel offering customization options for name and elements | $8M | 177 mo ago | 5 | Jonathan Jones Co-Founder | — | Acquired | 383 patents Genetically engineered crops for stress tolerance, high biomass, and carbon sequestration | — |
| 22 | BioChain Provider of products and services for clinical diagnosis, genomics, and proteomics | $7M | 116 mo ago | 24 24 → 40 (+67%) | Grace Tian CEO | WordPressMagentoCart Functionality+40 | Late Stage | — | — |
| 23 | Sepragen Bioprocess chromatography solutions for biologics, vaccines, and nutraceutical manufacturing | $5M | 21 mo ago | 19 19 → 32 (+68%) | Vinit Saxena Founder | WordPressMySQLPHP+20 | Series A | 7 patents Advanced bioreactors and sealed radial/axial flow chromatography columns for cell culture processing | — |
| 24 | Genturadx Molecular diagnostic platforms for clinical applications | $4M | 182 mo ago | 40 | — | — | Acquired | 8 patents Automated microfluidic cassettes for sample prep, reaction, detection, and evaporation control | — |
| 25 | Alpha Orthopaedics Develops non-invasive radio frequency devices for the treatment of musculoskeletal disorders | $3M | 184 mo ago | — | Diana Villegas Founder | — | Deadpooled | 10 patents Real-time optical monitoring and modulation of collagen/birefringent tissue in orthopedic applications | — |
| 26 | Aarvik Therapeutics Developer of antibody-drug conjugates for oncology targets | $1M | 9 mo ago | 9 | Sachdev Sidhu Co-Founder | Cart FunctionalitySquarespace CommerceSquarespace+10 | Seed | — | — |
| 27 | Planet Biotechnology Plant-based antibody therapeutics and preventative products for underserved medical needs | $761K | 14 mo ago | 5 | Elliott Fineman President and CEO | — | Early Stage | 42 patents Therapeutic Fc-fusion biologics targeting complement and viral entry receptors | — |
| 28 | Multispan Experts in cell-based assays, stable cell lines, and drug discovery | $600K | 213 mo ago | 6 | Helena Mancebo CEO | WordPressMySQLPHP+22 | Seed | 9 patents Engineering GPCR-expressing cell lines and vectors for pharmaceutical target screening | 2 launchs · 1 partnership |
| 29 | Sevident Develops 3-D scaffold based capture tool for disease diagnosis | $578K | 145 mo ago | — | Emily Stein Founder & President | — | Deadpooled | 14 patents Affinity capture platforms using molecular nets for analyte detection and sample preparation. | — |
| 30 | Frontier Bio Developer of engineered tissues to replace animal studies | $512K | 10 mo ago | 15 | Eric Bennett CEO | WixSentryBootstrap+10 | Seed | — | — |
| 31 | Anvil Biosciences Developer of nucleic acid-based therapeutics for rare autoimmune diseases | $446K | 144 mo ago | — | Jack Lin CEO & Co-Founder | — | Funding Raised | — | — |
| 32 | ProZyme Life sciences, diagnostics, and applied markets solutions provider | $321K | 177 mo ago | 47 | Sergey Vlasenko CEO & President | — | Acquired | 43 patents Improving glycan labeling/reduction and capillary electrophoresis analysis of carbohydrates | — |
| 33 | Cell Genesys Developing cell-based immunotherapies (vaccines) and oncolytic virus therapies to treat cancer | $310K | 207 mo ago | — | Raju Kucherlapati Co-Founder | — | Acquired | 239 patents Lentiviral vector production and cancer immunotherapy using engineered gene delivery systems | — |
Top 12 Life Sciences companies in Hayward
#1
Series C · Hayward, California · founded 2009 · 97 employees$33.9Mraised▾
Provider of web-based platform for labs management. It is a cloud-based platform that allows laboratories to streamline their communications, manage inventory, and purchase what they need to hit their milestones faster.
- Apr 2026Series C$23M
- Dec 2019Series B$5M
- Jan 2016Series B$17M
- Jul 2013Series A$4M
#2
Series D · Hayward, California · founded 2006 · 15 employees$262.3Mraised▾
Developer of an implant for pre-arthroplasty osteoarthritis patients. The lead product, the KineSpring Knee Implant System, is designed for patients with knee osteoarthritis. It's a partial load absorber that reduces knee joint load by up to 13 kg.
- Aug 2024Series D$62.7M
- Aug 2022Series C$40M
- Aug 2022Conventional Debt—
- Mar 2017Series C$50M
#3
Series F · Hayward, California · founded 2009 · 257 employees$490.3Mraised▾
Provider of biology-guided radiotherapy system. Its patented technology leverages Positron Emission Tomography (PET) which allows tumors to continuously signal their location during treatment and guides personalized radiation therapy. The technology has applications in the treatment of Lung, prostate, and Breast cancers.
- Nov 2023Series F$106.7M
- Jul 2022Conventional Debt$125M
- Mar 2022Series E$80M
- Mar 2021Series D$40M
#4
Series A · Hayward, California · founded 1984 · 27 employees$17.5Mraised▾
Provider of cell-based phenotyping technologies and assays. The company's technologies include the Biolog Microbial ID System which can rapidly identify over 2,900 species of aerobic and anaerobic bacteria, yeasts, and fungi, Rainbow Agar Chromogenic Media for microbial detection, EcoPlates for simplified microbial community analysis and Phenotype MicroArrays to quantitatively measure thousands of cellular phenotypes in parallel. The company also provides research services on Phenotype MicroArrays.
- Feb 2025Series A$16.1M
- Jan 2023Series A$17.5M
- Aug 2018Unattributed—
- Sep 2009Grant (prize money)$1.4M
#5
Seed · Hayward, California · founded 2021 · 9 employees$1.2Mraised▾
Developer of antibody-drug conjugates for oncology targets. It offer site-specific antibody-drug conjugation technology to develop antibody drug conjugates for the treatment of solid tumors.
- Oct 2025Seed—
- Nov 2024Seed$1.2M
- Aug 2021Seed—
#6
Deadpooled · Hayward, California · founded 2017 · 32 employees$80.7Mraised▾
Developer of cancer therapeutics using gene editing. It has a properitory platform TAGE (Targeted Active Gene Editors) delivers CRISPR nuclease effectors to selected cell in-vivo. It offers pipeline for immuno-oncology, hematology and ophthalmology.
- Sep 2023Grant (prize money)$533.9K
- Mar 2022Series B$36.5M
- Nov 2020Series A$30M
- Sep 2019Series A$6.9M
#7
Seed · Hayward, California · founded 2018 · 15 employees$511.8Kraised▾
Developer of engineered tissues to replace animal studies. The company is creating lab-grown human tissues in the areas of lung, brain, and blood vessels can be used for more accurate medical device testing, drug development, surgical training, and disease modeling.
- Aug 2025Seed—
- Aug 2021Grant (prize money)$255.9K
- Aug 2021Grant (prize money)$255.9K
- May 2020Seed—
#8
Early Stage · Hayward, California · founded 1994 · 5 employees$761Kraised▾
Plant-based antibody therapeutics and preventative products for underserved medical needs. Focused on discovering, developing, and commercializing innovative antibody-based solutions through genetically modified green plants. Specializing in plant-made antibodies, also known as "plantibodies," for significant unmet medical needs. Offers products like immunoadhesins for the treatment and prevention of inhalational anthrax and MERS coronavirus infection. Provides contract protein expression and purification services, collaborating on projects involving protein expression in tobacco plants. This biotechnology company is dedicated to advancing healthcare through sustainable and cutting-edge plant-based solutions, offering both therapeutic products and specialized services in protein expression.
- May 2025Grant (prize money)$596.9K
- 2024Grant (prize money)$600K
- 2023Grant (prize money)$600K
- 2020Grant (prize money)$3.2M
#9
Acquired · Hayward, California · founded 1991 · 23 employees$276.4Mraised▾
Developer of therapeutics for liver and other chronic diseases. The lead product of the company is Seladelpar is a potent, selective, orally active PPARδ agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangiti. Other products include MBX-2982 for Diabetic Hypoglycemia and CB-001 for inflammatory disorders.
- Aug 2021Grant (prize money)$100M
- Jan 2018Post IPO$5M
- Aug 2015Unattributed$325K
- Dec 2013Venture Debt$5M
#10
Series A · Hayward, California · founded 1987 · 19 employees$5Mraised▾
Bioprocess chromatography solutions for biologics, vaccines, and nutraceutical manufacturing. The company provides innovative tools and technologies for the development and manufacturing of life-saving biological drugs, vaccines, and diagnostics. Specializing in bioprocess chromatography, they offer a range of products including chromatography systems, columns, resins, and column packing systems. Their solutions cater to biologics drug manufacturing, enabling biologics drug scale-up, and health-enhancing human nutrition. They focus on providing high-throughput purification and rapid scale-up capabilities. The company is dedicated to quality management and meeting international standards. They offer services such as technical support, customer service, and customized engineering. Their technologies are used in the production of FDA-approved drugs and are designed to improve productivity, reduce costs, and accelerate time to market.
#11
Series A · Hayward, California · founded 2017 · 7 employees$12.7Mraised▾
Biotechnology company illuminating complex diseases with innovative diagnostic and life science solutions. They focus on creating innovative life-science solutions that combine advanced analytical performance, actionable data, and proprietary science. Their integrated sample-to-answer PCR molecular diagnostic system is intended for convenient use in decentralized clinical settings for diagnosis or on-site screening. They provide a PCR-based point-of-care molecular diagnostic system that gives a sample-to-answer in a short time while ensuring accuracy. They offer solutions that enable physicians to make informed treatment decisions faster. Their technology provides genuine insights from cell by cell, understanding that each cell is unique and possesses diverse clues that imply how biology will be. This company is focused on impacting the world through advanced diagnostics and life science solutions.
- Mar 2024Series A$10M
- Nov 2019Seed$2.7M
- Sep 2017Grant (prize money)$198.3K
#12
Deadpooled · Hayward, California · founded 1994 · 67 employees$220Mraised▾
Developer of a continuous monitoring system for use in the surgical intensive care unit (SICU). The company's lead product, the OptiScanner 5000, is an automated, bedside glucose monitoring system that measures values directly from plasma using spectroscopy technology to support clinicians in detecting changes more rapidly in critically ill patients.
- Mar 2019Series E$20M
- Feb 2018Series E$14.8M
- Jun 2016Series E$29.5M
- Jan 2013Series D$30.7M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.